U.S. Interventional Oncology Procedures Market Size, Share, Trends And Forecast 2026-2033 Minimally Invasive Innovation Drives 9.9% CAGR To USD 23.4 Billion
Dublin, Nov. 12, 2026 (GLOBE NEWSWIRE) -- "U.S. Interventional Oncology Procedures Market Size, Share & Trends Analysis Report 2026-2033" has been added to ResearchAndMarkets.com's offering.
The U.S. interventional oncology procedures market was valued at USD 10.8 billion in 2025 and is projected to increase from USD 12 billion in 2026 to USD 23.4 billion by 2033. The market is expected to expand at a compound annual growth rate of 9.9% from 2026 to 2033, supported by the rising prevalence of cancer, technological advancements in minimally invasive procedures, an expanding geriatric population, increased emphasis on early cancer detection, and sustained public and private investment.
Growth in cancer incidence is increasing demand for advanced, targeted treatment options across the U.S. healthcare system. Innovations in interventional oncology are improving procedural precision, supporting effective tumor destruction, and limiting damage to surrounding tissues. Advanced ablation systems also enable controlled and repeatable energy delivery, strengthening treatment reliability for tumors in bone and soft tissue.
In September 2022, Stryker's OptaBlate bone tumor ablation system received U.S. Food and Drug Administration clearance. The system incorporates patented micro-infusion technology to provide faster and more consistent ablations, including the simultaneous treatment of two vertebral body levels. Its application in painful metastatic tumors reflects the increasing clinical role of interventional oncology in pain management and cancer care.
Adoption of microwave ablation, cryoablation, irreversible electroporation (IRE), and radioembolization has increased as healthcare providers seek procedures associated with shorter hospital stays and fewer complications than conventional surgery. Microwave ablation systems are gaining particular attention because of their faster heating, larger ablation zones, and efficacy in highly vascular tumors.
In July 2024, IceCure Medical announced U.S. FDA clearance for its next-generation XSense cryoablation system with CryoProbes. The technology is intended for tumor destruction through controlled freezing and highlights continued innovation in minimally invasive oncology procedures. Advancements across ablation platforms are helping clinicians perform more outpatient and same-day treatments, improving patient convenience while supporting lower healthcare costs.
The growing U.S. population aged 65 years and older is another important market driver because cancer incidence rises substantially with age. This population reached approximately 59.8 million in 2023, expanding the number of patients who may be eligible for targeted, minimally invasive cancer procedures.
Early cancer detection initiatives are also expected to increase procedural volumes. In March 2024, the U.S. Centers for Disease Control and Prevention emphasized routine screening for breast, colorectal, cervical, and lung cancers through national awareness programs. Continued focus on screening, diagnosis, and preventive healthcare is supporting earlier treatment and broader adoption of interventional oncology procedures.
Investment in research and clinical infrastructure is accelerating market innovation. In December 2024, the Society of Interventional Radiology (SIR) Foundation awarded USD 1.5 million to four research projects, including two focused on interventional oncology. One project will develop a novel model of hepatocellular carcinoma (HCC), while another will apply genetic subtyping to precision interventions for HCC.
Report Segmentation
The report provides revenue forecasts and analyzes industry trends across sub-segments from 2021 to 2033. Market segmentation covers technique, procedure, cancer type, and end-use.
Technique Outlook (Revenue, USD Billion, 2021 - 2033)
- Ablation Therapies Embolization Therapies Biopsy Techniques Targeted Therapy Delivery Systems Image-Guided Procedures
Procedure Outlook (Revenue, USD Billion, 2021 - 2033)
- Tumor Ablation Tumor Biopsy Vascular Interventions Palliative Care
Cancer Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Liver Cancer Lung Cancer Kidney Cancer Prostate Cancer Others
End-use Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospitals Ambulatory Surgical Centers Others
Key Report Benefits
- Detailed U.S. interventional oncology procedures market estimates and forecasts Analysis of major growth drivers, emerging technologies, and industry trends Revenue assessments across technique, procedure, cancer type, and end-use segments Competitive landscape and market presence insights Evaluation of product innovation and evolving treatment approaches Actionable intelligence to support strategic planning, investment decisions, and revenue opportunities
Companies Featured
- Medtronic Boston Scientific Corporation Johnson & Johnson MedTech Cook Medical AngioDynamics Inc. Stryker Corporation Terumo Corporation Siemens Healthineers AG Baxter International Inc. Becton, Dickinson and Company B. Braun GE Healthcare
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment